what is known already: Endometriosis has a strong genetic basis. Recent genome-wide association and linkage studies have reported a significant association of endometriosis with 7p15.2, 9p21 and 10q23-26 loci. PTEN, which maps to 10q23.3, acts as a tumor suppressor gene through the action of its phosphatase protein product, phosphatase and tensin homolog (PTEN). This phosphatase is involved in the regulation of the cell cycle, and mutations of PTEN are a step in the development of many cancers. participants/materials, setting, methods: LOH on 10q, 9p and 7p was analyzed in analogous ectopic-eutopic endometria along with blood samples from 32 advanced stage endometriosis patients by PCR-GeneScan analysis. Genotyping of PTEN was carried out on genomic DNA of analogous ectopic-eutopic endometria (n ¼ 32) as well as blood samples from 720 patients and 500 controls by PCRsequencing analysis to explore somatic and germ-line mutations, respectively. The levels and distribution of PTEN, p-Akt, p-Bad and p27 were analyzed in the eutopic endometria of patients (n ¼ 5) and controls (n ¼ 5) using western-blot and immunohistochemistry.
Introduction
Endometriosis (MIM 131200) is a complex gynaecological disorder characterized by the presence of endometrial glands and stroma within extrauterine sites, most commonly the ovaries and peritoneum (Giudice and Kao, 2004) . The disease affects 5-10% of women of reproductive age and up to 30 -50% of women with infertility. Although symptoms vary, they commonly include severe pelvic pain, severe dysmenorrhea and subfertility. The causes of endometriosis remain uncertain despite over 100 years of hypothesis-driven research. The strong familial tendency of the disease suggests possible heritable genetic susceptibility (Zondervan et al., 2001) . We have demonstrated a correlation between various candidate genes and risk of endometriosis in Indian women (Bhanoori et al., 2005a (Bhanoori et al., ,b, 2007 (Bhanoori et al., , 2008 Govatati et al., 2012a Govatati et al., ,b,c, 2013a . The emerging evidence strongly suggests that the disease has a polygenic and multifactorial basis (Tempfer et al., 2009) . Recent large genome-wide association studies (GWASs) and genomewide linkage studies (GWLSs) reported a significant association of endometriosis with 7p15.2, 9p21 and 10q23-26 loci (Treloar et al., 2005; Uno et al., 2010; Painter et al., 2011a,b; Nyholt et al., 2012) . GWAS detect low-risk and common genetic variants predisposing to complex genetic diseases in the general population, while GWLS detect higher risk variants in related individuals. However, both of the studies could not reveal somatic risk factors even though the disease has a somatic origin, partly or entirely. In this context, we suspect some somatic allelic changes at the previously reported risk loci by GWAS (7p15.2, 9p21) and/or . In the present study, we aimed to test this hypothesis using analogous endometriotic and normal endometria along with blood samples from patients with endometriosis.
Pathohistologically, endometriosis is a benign lesion but often displays characteristics that are associated with malignancy. Clinical observations and in vitro experiments revealed the invasive and proliferative nature of endometriotic cells (Giudice and Kao, 2004) . Loss of heterozygosity (LOH) and microsatellite instability (MSI) are common genetic alterations found throughout the genome in most tumor types (Wooster et al., 1994) . The gene PTEN (MIM 601728; phosphatase and tensin homolog deleted on chromosome 10) is one of the most important tumor suppressors, located at 10q23.3 locus (Song et al., 2012) . Frequent LOH at 10q23.3 and mutations of PTEN have been found in several diseases, including cancer (Kong et al., 1997; Scarisbrick et al., 2000; Canbay et al., 2013) . In addition, functional loss of just a single PTEN allele is enough to confer a growth advantage (Di Cristofano et al., 2000) . PTEN mutations without LOH in the PTEN locus or LOH in the PTEN locus without PTEN mutations can reduce the function of PTEN (Di Cristofano et al., 2000; Chen et al., 2012) . Loss of PTEN function is an early event in endometrial tumorigenesis (Mutter et al., 2000) . Although PTEN alterations have been extensively investigated in several human diseases, studies related to endometriosis are few and inconsistent (Sato et al., 2000; Prowse et al., 2005; Ali-Fehmi et al., 2006; Treloar et al., 2007) . In the present study, we analyzed LOH, MSI and PTEN alterations (both somatic and germ-line) in endometriosis.
PTEN encodes a protein (47.15 kD) with dual phosphatase activity that dephosphorylates phosphatidylinositol-3,4,5-triphosphate (PIP3), a second messenger of phosphatidylinositol-3-kinase (PI3K) (Maehama and Dixon, 1998; Di Cristofano et al., 2000) . PTEN antagonizes PI3K activity and negatively regulates its downstream target, the serine/ threonine kinase Akt (Stambolic et al., 1998) . Phosphorylated Akt modulates the activity of a variety of downstream proteins, such as the proapoptotic factor Bad, which suppresses apoptosis and promotes cell survival (Datta et al., 1997; Del Peso et al., 1997) . On the other hand, PTEN inhibits cell growth and induces a G1 arrest with an increase in the cell cycle kinase inhibitor p27 (Ramaswamy et al., 1999) .
Loss of PTEN function with subsequent activation of PI3K/Akt signaling pathway is a pivotal event in the development of a tumor (Ramaswamy et al., 1999) . In addition, the nuclear/cytoplasmic subcellular distribution of PTEN may be important for its functional regulation (Lian and Di Cristofano, 2005) . Decreased PTEN expression and increased PI3K/Akt activity has been reported in several diseases including cancer (Scrima et al., 2012; Bradtmö ller et al., 2012) . Diminished PTEN expression has also been reported in some cases of endometriosis (Martini et al., 2002; Zhang et al., 2010; Rai and Shivaji, 2011) . However, there are no reports on PTEN-PI3K/Akt involvement in endometriosis. To clarify whether and how PTEN and the PI3K/Akt pathway relates to endometriosis we examined, for the first time, the pathway-related proteins PTEN, p-Akt, p-Bad and p27 in phase-matched eutopic endometria of patients and controls.
Materials and Methods
Tissue collection for the analysis of LOH, MSI and PTEN somatic mutations Analogous ectopic and eutopic endometria were collected from 32 premenopausal unrelated women of South Indian origin with surgically confirmed moderate-severe [Revised American Fertility Society classification system (rAFS): Stages III -IV] endometriosis. The samples were collected from Infertility Institute and Research Centre (IIRC), Secundrabad, India (n ¼ 7) and Vasavi Medical and Research Centre, Hyderabad, India (n ¼ 25). Each pair of ectopic -eutopic endometria was collected from the same patients to minimize the genetic heterogeneity. In addition, we collected blood samples from the same patients to confirm the LOH/MSI and/or heterozygous somatic mutations in endometriotic tissues because it is possible that the apparent incidence may be attributed to contamination by the surrounding non-endometriotic cells. Tissue samples were frozen immediately in the operation room and stored at 2808C until isolation of genomic DNA was performed.
Blood samples for the analysis of PTEN germ-line mutations A total of 720 premenopausal unrelated Indian women with moderatesevere (Stage III -IV) endometriosis staged using the rAFS classification system (rAFS, 1997) were recruited at the IIRC, Secundrabad, India (South Indian or Dravidian linguistic group, n ¼ 370) and Institute of Reproductive Medicine (IRM), Kolkata, India (North Indian or Indo-European linguistic group, n ¼ 350). All women had a transvaginal ultrasound scan (TVS) at screening followed by a laparoscopy to confirm the diagnosis (rAFS III ¼ 264; IV ¼ 456). The patients had different forms of endometriosis, such as peritoneal lesions, adhesions and endometrioma. Women with other ovarian cysts, adenomyosis, ovarian cancer, fibroids and Stage I or II endometriosis were excluded from the study. The aim was to focus on patients with more severe endometriosis (Stages III and IV) because the more severe forms include ovarian cystic disease, which almost certainly has a different etiology to peritoneal forms, and the diagnosis is usually unequivocal, which is not the case for Stages I and II. The mean + SD age of patients was 26.5 + 5.5 (range 20 -40) years. All the patients complained of Mutations in PTEN and endometriosis dysmenorrhea (mild ¼ 45%; moderate 31%; severe 24%) and 75% had dyspareunia. Most women (98.1%) were infertile (primary 82%; secondary 18%).
Five hundred women (250 each from IRM and IIRC) were recruited from the same clinic population and had an equal opportunity to be identified as cases, thereby meeting the criteria for appropriate controls, as set by Zondervan et al. (2002) . The controls consisted of 431 (86.2%) women with no evidence of endometriosis on TVS and laparoscopy and 69 (13.8%) women with no evidence of an ovarian endometrioma on TVS (and no clinical symptoms of endometriosis) who therefore did not subsequently have a laparoscopy. Their mean + SD age was 27.9 + 4.95 years (range 22 -40). Seventy-six percent had primary and 24% had secondary infertility. Among the symptomatic controls, 27% complained of mild dysmenorrhea and 24% complained of dyspareunia.
Peripheral blood samples (5 ml) were collected from both groups into EDTA vacutainers and stored at 2808C until use.
Tissue collection for protein analysis
Secretory phase endometrial tissue was obtained from the uterine fundus of endometriosis patients (n ¼ 5) and controls (n ¼ 5) by curettage at the time of laparoscopy. Each sample was divided into two portions: one was immediately immersed in 4% paraformaldehyde in 0.05 M of Tris -HCl buffer (pH ¼ 7.4) at 48C for at least 24 h and embedded in paraffin for histological examination. Another portion was rinsed in ice cold phosphate-buffered saline (PBS) on ice to remove excess blood and then rapidly frozen in liquid nitrogen and stored at 2708C for subsequent western immunoblot assay. Histological assessment of endometrial morphology was carried out using standard criteria (Noyes et al., 1950) .
Ethical approval
Written informed consent was obtained from all participants. The Institutional Review Board of the Centre for Cellular and Molecular Biology, Hyderabad, approved the study.
DNA extraction
Genomic DNA was extracted from 1 ml of whole blood by the salting out method (Miller et al., 1988) . For tissue samples, an initial proteinase K digestion was performed followed by the salting out procedure.
LOH and MSI analysis
Analogous ectopic and eutopic endometrial tissues along with the blood samples collected from the patients (n ¼ 32) were analyzed for LOH and MSI on 10q, 9p and 7p by PCR-GeneScan analysis using 13 highly polymorphic fluorescent labeled microsatellite markers (Supplementary data, Table SI ). Detailed methodology is available in Supplementary data.
PTEN genotyping
The genotyping of PTEN was carried out in a randomized, blinded fashion by PCR-Sequencing analysis, as described (Govatati et al., 2012a) . Sixteen pairs of primers were used to amplify 7.2 kb region of PTEN that includes the entire promoter, coding region, exon-intron boundaries, splicing sites and 3 ′ untranslated region (UTR). The primers and PCR conditions used are given in Supplementary data, Table SII. The PCR products were analyzed using a 1.5% agarose gel and were then sequenced with a Taq-Dye deoxyterminator cycle sequencing kit (Applied BioSystems, USA) using an automated ABI 3770 DNA sequencer (Applied BioSystems, USA). Genotype calling was performed using Chromas V.2 software (Technelysium Ltd., Australia).
PTEN mutation analysis
The individual sequences were compared against the reported genomic sequence of PTEN using Auto Assembler-Ver 2.1 (Applied Biosystems, Foster City USA). Sequences were aligned using CLUSTAL X and mutations were noted using MEGA software ver 3.1. Sequence differences found between ectopic endometrial DNA and analogous eutopic endometrial and/or blood DNA were scored as 'somatic mutations' while the sequence variations found in both ectopic and analogous eutopic as well as in blood DNA were scored as germ-line variations. Each was then checked against the database. Those not recorded in the database were categorized as novel PTEN mutations and those that appeared in the database were reported as PTEN polymorphisms.
Immunohistochemical analysis
Immunohistochemical analysis of PTEN, p-Akt, p-Bad and p27 was performed on the sections of secretory phase eutopic endometria from cases (n ¼ 5) and controls (n ¼ 5), as described (Govatati et al., 2012b) . Briefly, after incubation with primary antibody [PTEN (1:200) , p-Akt (1:250), p-Bad (1:50) obtained from Cell Signaling Technology, USA; p27 (1:200) obtained from Santa Cruz Biotechnology, USA] for 2 h at room temperature, tissue sections were washed in PBS and incubated with horseradish peroxidase-conjugated secondary goat anti-rabbit antibody (1:1000, DAKO EnvisionTM+ System, DAKO Corp.) for 30 min. Then the sections were washed and treated with 3-3 ′ -diaminobenzidine chromogen for 5 -10 min, counterstained with hematoxylin and mounted with DPX. Negative controls were obtained by substituting primary antibodies with non-immune rabbit serum. Staining intensity was scored for each tissue and each antibody using Image J software. All individual tissue samples were stained at one time for consistency and quantification was performed blinded to the pathology.
Western blot analysis
Protein extraction and western blot analysis were performed as described by Bhanoori et al. (2008) using secretory phase eutopic endometria from cases (n ¼ 4) and controls (n ¼ 5). Briefly, after blocking with 5% (w/v) non-fat milk in TBST [Tween 0.1% (v/v) in TBS] for 1 h at room temperature, the membranes were washed and incubated with the primary antibody [PTEN (1:1000), p-Akt (1:1000), p-Bad (1:1000) obtained from Cell Signaling Technology, USA; p27 (1:1000) obtained from Santa Cruz Biotechnology, USA] prepared in TBST containing BSA 1% (w/v) for 1 h. The membranes were then washed and incubated with the appropriate horseradish peroxidaseconjugated secondary antibody (1:10000, Sigma) for 1 h at room temperature. Then, the membranes were washed and the antigen -antibody complexes were detected using a chemiluminescence reagent kit (GE health care, USA). Band intensity in the western blots was determined using imageJ software.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (V 11.0). The genotype distribution among subjects was tested for Hardy -Weinberg equilibrium (HWE) using Fisher's exact test. The allele ratios and genotype distributions of cases and controls were analyzed with Pearson x 2 or Fisher's exact test. Haplotype frequencies for multiple loci and the standardized disequilibrium coefficient (D ′ ) for pair-wise linkage disequilibrium (LD) were assessed by Haploview Software (Barrett et al., 2005) . Bonferroni correction was used to adjust the significance level of a statistical test to protect against Type I errors when multiple comparisons were being made. The Student's t-test was used to analyse differences between immunoblot band densities; P , 0.05 was considered statistically significant based on three or more independent experiments.
Results

LOH and MSI analysis
All ectopic endometrial tissues showed LOH for at least one microsatellite marker analyzed (Table I) while none of the analogous eutopic endometria and blood samples showed LOH at any of the loci analyzed. This indicates the purity of ectopic endometrial samples.
The observed LOH frequency at different microsatellite loci analyzed was-29.03% (D7S516), 9.4% (D9S161), 21.9% (D9S171), 10.7% (D10S608), 15.6 (D10S587), 41.9 (D10S215) and 48.4% (D10S541). Six markers (D7S510, D7S484, D9S157, D10S579, D10S217 and D10S212) did not show any molecular alterations (Table I) . Our results indicate the maximum LOH frequency at 10q23.3 locus compared with the other loci investigated [D10S215+ D10S541 ¼ 84.4% (27/32)]. PTEN has been mapped to this region and is closely flanked by D10S215 and D10S541 markers. None of the samples analyzed showed MSI.
PTEN somatic mutations in endometriosis
Seven novel somatic mutations ( Fig. 1) were detected in 17/32 (53.1%) ectopic endometrial tissues. One of these was a frame-shift insertion located in exon 5 and the remaining six were located in introns and 3 ′ UTR of PTEN (Table II) . Most of the somatic mutations occurred only once, but the frame-shift insertion at 10:89692992-89692993 was detected in 11/17 ectopic tissues positive for somatic mutations. Furthermore, among the 17 ectopic tissues positive for somatic mutations, 13 (76.5%) showed LOH at 10q23.3 locus (Tables I and II) .
PTEN germ-line mutations in endometriosis
We detected 23 PTEN germ-line single nucleotide polymorphisms (SNPs) in patients and/or controls (Table III) . All 23 identified SNPs were base substitutions. Amongst both patients and controls, the genotype distributions of individual SNPs as well as the allele system were all in the HWE (P . 0.05). The minor allele frequencies (MAFs) of most of the identified SNPs ranged from 0.14 to 0.42% in patients and from 0.2 to 0.4% in controls. The MAF for 4 of the 23 identified SNPs (rs1903858, rs185262832, rs10490920 and rs555895; Table III ; Fig. 2 ) ranged from 1.81 to 2.5% in patients and from 1.4 to 2.6% in controls. We found no evidence for associations between endometriosis and individual SNPs in PTEN for either the allelic or the genotypic association tests.
Haplotype analysis
To analyse the combined effects of PTEN germ-line polymorphisms on endometriosis risk, the haplotype frequencies for multiple loci and the standardized disequilibrium coefficient (D ′ ) for pair-wise LD were estimated. In this study we included only SNPs with an MAF ≥ 2%. Our results showed different patterns of LD for patients and controls (Fig. 3) . However, we did not observe significant LD between any of the four SNPs analyzed. Our data indicate 10:89653686A/10:89685398G/10:89685643T/ 10:89720907T as the most common PTEN haplotype in Indian women. The relative risk of each haplotype was calculated by using this as reference (Table IV) 
Immunohistochemical analysis
Our results showed different pattern of PTEN staining in case versus control tissues (Fig. 4A) . PTEN immunoreactivity was strong and nearly homogeneous in eutopic endometria of controls, while comparatively lower and heterogeneous in patients (P , 0.0001). Furthermore, nuclear PTEN was more frequently reduced compared with cytoplasmic PTEN in eutopic endometria of patients (data not shown). The PTEN immunostaining was weaker or negative in glands.
For p-Akt, eutopic endometria of patients showed more intense cytoplasm and/or nuclear immunostaining than the controls (P , 0.0001; Fig. 4B ). p-Bad immunoreactivity was predominantly detected in cytoplasm of endometrial glands compared with stroma. Less p-Bad immunostaining was observed in controls than in cases (P , 0.0001; Fig. 4C ). In case of p27, nearly homogeneous nuclear immunoreactivity was detected in both case and control tissues. The degree of p27 immunostaining did not appear to differ in cases versus controls (P ¼ 0.777; Fig. 4D ).
Western blot analysis
Western blot results confirmed our immunohistochemistry data. The level of PTEN in eutopic endometria of patients was significantly lower than that in controls (P , 0.0001; Fig. 5A ). In contrast, the p-Akt and p-Bad levels were significantly higher in eutopic endometria of patients than in controls (P , 0.0001; Fig. 5B -C) . The level of p27 did not appear to vary between case and control tissues (P ¼ 0.624; Fig. 5D ). 
Discussion
Recent GWAS and GWLS revealed a significant association of endometriosis with three different chromosomal regions. Among them, Treloar et al. (2005) conducted a GWLS of 1176 families (Australian and UK) and reported a region of significant linkage on chromosome 10q. Their fine mapping results indicate that the 95% confidence interval for MLS (maximum LOD score) peak at 148.75 cM spans 15 cM, from 139.49 (10q26.11) to 154.77 cM (10q23.33). The major candidate genes in this region are EMX2 (MIM 600035) and PTEN. EMX2 (10q26.1) encodes a transcription factor required for reproductive tract development, while PTEN (10q23.3) is a potent tumor suppressor which has been implicated in the malignant transformation of ovarian endometriosis (Bischoff and Simpson, 2000; Sato et al., 2000) . However, the recent high-density fine-mapping of 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19 (Painter et al., 2011b) . Gene CYP2C19 plays a central role in the metabolism of drugs and estrogen including conversion of estradiol to estrone, and the production of their hydroxylation metabolites (Cribb et al., 2006) . A recent GWAS in Japanese women reported significant association of endometriosis with rs10965235 (P ¼ 5.8 × 10
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, odds ratio ¼ 1.44), which is located in CDKN2BAS on chromosome 9p21, encoding the cyclin-dependent kinase inhibitor 2B antisense RNA and possible associations with rs13271465 on 8p22 and rs16826658 on 1p36 (Uno et al., 2010) . Another recent GWA scan with 3194 surgically confirmed endometriosis cases and 7060 controls from Australia and UK reported significant association of endometriosis with rs12700667 (7p15.2) (Painter et al., 2011a) . rs12700667 is located in an intergenic region upstream of the candidate genes NFE2L3 and HOXA10. The closest gene, NFE2L3 is located 331 kb downstream of rs12700667 and is highly expressed in placenta, while HOXA10 is located 1.35 Mb downstream of rs12700667 and encode members of the 'homeobox A' family of transcription factors that plays a crucial role in uterine development. All these observations are interesting but could not reveal somatic risk factors even though the disease has a somatic origin, in partly or entirely. This directed our attention on present investigation.
In this study, we confirmed a higher frequency of LOH at 10q23.3 (84.4%) in ectopic endometria of patients. In addition, we detected a considerable level of LOH at 10q26.1 (15.6%), 9p21 (21.9%) and 7p15.2-15.1 (29.03%) loci, which indicates their possible association with endometriosis. However, in the present study we focused our attention more on PTEN (and associated genes) as we observed the maximum LOH at 10q23.3 locus. LOH at PTEN locus have been reported in several types of disease including tumors (Kong et al., 1997; Scarisbrick et al., 2000) ; however, only three studies were documented in endometriosis. Among them, the first study has demonstrated higher LOH frequency (56.5%) at 10q23.3 in 23 cases of solitary endometriotic cysts (Sato et al., 2000) . In addition, they reported common LOH events in cases of endometriosis with ovarian tumors. However, they did not report LOH solely in endometriosis. In the second study, Prowse et al. (2005) have reported no LOH at the PTEN locus along with other potential gene loci in which LOH has been previously detected. They claimed that most of the previous investigations were affected by flawed data, mainly caused by sample crossover and/or contamination. In the present study, for the first time we included three types of tissues (ectopic, eutopic tissues and blood) from each patient in the LOH analysis to avoid risks from such kind of contamination. The third study has demonstrated a significant difference in LOH between endometriosis (4.3%) and ovarian carcinoma (23.5%) at PTEN loci and suggested that it may possibly be an important molecular event in the progression of endometriosis to carcinoma (Ali-Fehmi et al., 2006) . Furthermore, we observed PTEN somatic mutations in 17 (53.1%) ectopic endometria, and 13 (76.5%) of these 17 were accompanied by LOH at 10q23.3 (Table II) . Only one study has evaluated PTEN somatic mutations in endometriosis (Sato et al., 2000) and showed that 7 of 34 (20.6%) solitary endometriotic cysts showed PTEN somatic mutations and 5 of these seven cases were accompanied by LOH at 10q23.3. Our results are in agreement with this finding; however, in the present study we observed a comparatively higher number of PTEN somatic mutations and LOH events. This could be because of the larger PTEN region ( 7.2 kb) analyzed in our study and/or ethnic variation between populations studied. Among the 17 ectopic tissues with PTEN somatic mutations, 11 (64.7%) showed an insertion of 'A' at 10:89692992-89692993. 'Variant Effect Predictor' software predicted this mutation as a 'frameshift variant with the feature of elongation' (position in cDNA: 1833-1834; position in protein: 159). It is located in exon 5 which includes the N-terminal phosphatase domain of PTEN. This domain is defined by the first 185 amino acids (exon 1-6) of PTEN and has an important biological role in lipid and protein phosphatase activity (Eng, 2003) . Some studies showed a higher frequency ( 30%) of somatic and/or germ-line mutations in this catalytic core (Tunca et al., 2007) . In addition, in vitro studies revealed that PTEN mutations in this catalytic core motif cause loss of lipid phosphatase activity (Eng, 2003) . However, the exact role of this mutation in the pathogenesis of endometriosis is currently unknown. Further extensive functional studies are necessary to elucidate the role of this mutation in endometriosis.
Our results showed no association between PTEN germ-line variants and endometriosis risk. Treloar et al. (2007) have analyzed 15 selected PTEN germ-line SNPs and endometriosis risk in Australian population and reported no association. In their study they focused mainly on SNPs with .5% MAF and hence did not analyse any of the coding region variants. In the present study, we covered comparatively larger PTEN region ( 7.2 kb) with .50 reported SNPs that covers entire coding region, promoter, exon-intron boundaries, splicing sites and 3 ′ UTR. We report here 23 PTEN germ-line SNPs in patients and/or controls while all the remaining variants were monomorphic in our population (Table III) . The genotypes and allelic distributions of identified SNPs did not differ between the controls and patients with endometriosis. Among the identified 23 germ-line SNPs, 4 showed a higher MAF in both cases and controls. Interestingly, the observed MAF of these four SNPs was much higher than their reported global MAF (Table III) They may be specific to the Indian population. LD analysis of these SNPs showed no significant difference (D ′ ) between cases and controls which is in agreement with the previous report (Treloar et al., 2007) . Further studies with more subjects and genotyping of the entire gene are necessary to better elucidate the correlation between PTEN germ-line variants and endometriosis. Our western blot and immunohistochemical analysis revealed an aberrant and decreased PTEN expression in eutopic endometria of patients compared with controls ( Figs 4A and 5A ). Loss of PTEN is common in various types of tumors including endometriosis (Martini et al., 2002; Zhang et al., 2010; Rai and Shivaji, 2011; Bradtmö ller et al, 2012) . However, more specifically, we observed greater loss of nuclear PTEN in eutopic endometria of patients than in controls. Previous studies indicate that nuclear PTEN loss and an impaired nuclear/ cytoplasmic PTEN ratio may contribute to tumorigenesis (Lian and Cristofano, 2005) . Nuclear PTEN interacts with anaphase-promoting complex/cyclosome (APC/C), promotes APC/C association with CDH1 and thereby enhances the tumor-suppressive activity of the APC-CDH1 complex (Song et al., 2011) , while cytoplasmic PTEN negatively regulates the PI3K/Akt signaling by its function as a lipid phosphatase (Maehama and Dixon, 1998) .
Furthermore, our results showed increased Akt phosphorylation along with PTEN loss in eutopic endometria of patients (Fig. 4A, 5A  and 4B , 5B). In general, Akt is activated as a result of PI3K activity. Once activated, PI3K phosphorylates PIP2 to form PIP3 by which Akt can bind correctly to the cell membrane, where Akt can be activated by phosphorylation by its activating kinases such as phosphoinositidedependent kinases 1 and 2 (PDK1 and PDK2). Activated Akt then exerts its functions via its kinase activity. PI3K-dependent Akt activation can be regulated by PTEN, which acts as a phosphatase to dephosphorylate PIP3 back to PIP2 and so removes the membrane-localization factor from the Akt signaling pathway (Ramaswamy et al., 1999) . Without correct localization, the kinase activation of Akt significantly decreases. Involvement of PI3K/Akt signaling in endometriosis has been investigated by a few scientific groups (Gentilini et al., 2007; Cakmak et al., 2009; Rai and Shivaji, 2011) . Here, for the first time, we found PI3K/ Akt signaling overactivity and PTEN loss in eutopic endometria of patients. Decreased PTEN expression and enhanced Akt activity can probably be attributed to the adhesion and proliferation of endometriotic cells on ectopic sites.
Bad, a downstream target of Akt, also showed higher phosphorylation in eutopic endometria of patients compared with controls (Figs 4C and 5C) . Bad is a proapoptotic member of the Bcl-2 family that promotes cell death by displacing Bax from binding to Bcl-2 and Bcl-xL (Yang et al., 1995) . Activated Akt phosphorylates Bad at 'Ser136 ′ which results in the inactivation of Bad and enhancement of cell survival (Datta et al., 1997; Del Peso et al., 1997) . Loss of PTEN and increased phosphorylation of Akt and Bad in eutopic endometria of patients indicate their possible association with endometriosis. p27 is a member of the Cip/Kip family of cyclin-dependent kinase inhibitors and inhibits cell growth and induces a G1 arrest by binding to CDK2/cyclin E and other CDK/cyclin complexes (Kato et al., 1994) . Elevated levels of p27 have been reported in quiescent cells and in cells treated with cAMP or other negative cell cycle regulators. On the other hand, down-regulation of p27 has been observed in cells treated with interleukin-2 or other mitogens, which involve phosphorylation and ubiquitin-proteasome pathway-based degradation of p27 (Lloyd et al., 1999) . Furthermore, increased growth activity accompanied by the down-regulation of p27 was observed in PTEN null embryonic stem cells (Sun et al., 1999) . This effect could be dependent on phosphorylation and activation of Akt. In the present study we did not find any significant difference in p27 expression between eutopic endometria of patients and controls. Additional studies may be required to elucidate the role of p27 in pathophysiology of endometriosis. In conclusion, we determined for the first time a high frequency of LOH at 10q23.3 compared with the other two significant loci which have been reported by GWAS. We also evaluated the profile of somatic and germ-line variations of PTEN in endometriosis. In addition, we have shown the down-regulation of PTEN and over-activation of PI3K/Akt pathway-related genes in eutopic endometria of patients. Although further work is necessary to understand the potential link between PTEN-PI3K/Akt and endometriosis, our findings may lead to new insights into the pathophysiology of endometriosis.
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